A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.

Study Identifier
M25-776
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

Study Details

Medical Condition
  • Healthy Volunteer
  • Study Drug
  • ABBV-243
  • Placebo
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 60 Years

    Protocol Summary

    The objective of this study is to assess the safety, tolerability, pharmacokinetics and immunogenicity of either single ascending intravenous (IV) doses of ABBV-243 or single ascending subcutaneous (SC) doses of ABBV-243 in healthy adult participants (Part 1), and a single intravenous (IV) dose in healthy Asian adult volunteers (Part 2

    There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

    Study Locations

    Location
    Status
    Location
    Acpru /Id# 279789
    Grayslake, Illinois, United States, 60030
    Status
    Recruiting